Board meeting on 27 Oct to consider Q2 FY27 results

Revenue growth above 20%EBITDA margin expansionResults View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.9%Reaction day

₹194.00

prior close

₹197.90

announcement price

In-mkt

timing

Nifty Smallcap 250market+0.1%+1.9% vs market

Pharmaceuticals peers, median of 173sector+0.0%+1.9% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Smallcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.7

15m

-0.6

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.9+0.1+1.9+0.0+1.9

Next day

+0.0-1.1+1.1-1.2+1.2

-1.8-3.3+1.5-3.0+1.2

+0.5-4.4+4.9-3.9+4.4

-1.5-7.0+5.5-5.1+3.6

+0.5-6.0+6.5-3.9+4.4

+18.9-3.6+22.5-0.9+19.8

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma has informed stock exchanges about a Board meeting scheduled on Tuesday, 27 October 2026 to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2026. The trading window for dealing in company securities remains closed from 1 October to 29 October 2026. This is a routine compliance intimation under SEBI Listing Regulations.

Likely market impact

Routine advance notice of upcoming Q2 results; watch for the outcome on 27 October 2026.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹2,617 Cr	₹2,044 Cr	+28.1%
Operating profit	₹27.96 Cr	−₹126.6 Cr	turned positive
Profit after tax	₹5.03 Cr	−₹99.22 Cr	turned positive
EBITDA margin	13.3%	7.8%	+5.6 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.